Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Esperion Therapeutis.Inc. buy nadine86

Start price
€1.37
11.05.23 / 50%
Target price
-
11.06.23
Performance (%)
-6.13%
End price
€1.29
12.06.23
Summary
This prediction ended on 12.06.23 with a price of €1.29. With a performance of -6.13%, the BUY prediction by nadine86 finished with a loss. nadine86 has 50% into this prediction

Esperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.

Performance without dividends (%)
Name 1w 1m
Esperion Therapeutis.Inc. 4.053% 4.053%
iShares Core DAX® 0.000% -2.064%
iShares Nasdaq 100 0.626% -2.884%
iShares Nikkei 225® 1.568% -5.892%
iShares S&P 500 0.334% -2.281%

Comments by nadine86 for this prediction

In the thread Trading Esperion Therapeutis.Inc.
Prediction Buy
Perf. (%) -6.13%
Target price
Change
Ends at 11.06.23

Die von nadine86 gewählte maximale Laufzeit wurde überschritten